BACKGROUND: Psoriasis is a pathological condition characterized by immune system dysfunction and inflammation. Patients with psoriasis are more likely to develop a wide range of disorders associated with inflammation. Serum levels of various substances and their combinations have been associated with the presence of the disease (psoriasis) and have shown the potential to reflect its activity. The aim of the present study is to contribute to the elucidation of pathophysiological links between psoriasis, its pro-inflammatory comorbidity metabolic syndrome (MetS), and the expression of clusterin and elafin, which are reflected in the pathophysiological "portfolio" of both diseases. MATERIAL AND METHODS: Clinical examinations (PASI score), ELISA (clusterin, elafin), and biochemical analyses (parameters of MetS) were performed. RESULTS: We found that patients with psoriasis were more often afflicted by MetS, compared to the healthy controls. Clusterin and elafin levels were higher in the patients than in the controls but did not correlate to the severity of psoriasis. CONCLUSION: Our data suggest that patients with psoriasis are more susceptible to developing other systemic inflammatory diseases, such as MetS. The levels of clusterin and elafin, which are tightly linked to inflammation, were significantly increased in the patients, compared to the controls, but the presence of MetS in patients did not further increase these levels.

Clinic of Dermatology and Venereology University Hospital Hradec Kralove 50005 Hradec Králové Czech Republic

Institute of Clinical Biochemistry and Diagnostics University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove Charles University 50005 Hradec Kralove Czech Republic

Institute of Clinical Immunology and Allergology University Hospital and Faculty of Medicine in Hradec Kralove Charles University 50005 Hradec Kralove Czech Republic

Institute of Hygiene and Preventive Medicine Faculty of Medicine in Hradec Kralove Charles University 50038 Hradec Kralove Czech Republic

Institute of Pathological Physiology Faculty of Medicine in Hradec Kralove Charles University 50003 Hradec Kralove Czech Republic

Transfusion Center University Hospital 50005 Hradec Kralove Czech Republic

Zobrazit více v PubMed

Boehncke W.-H., Schön M.P. Psoriasis. Lancet. 2015;386:983–994. doi: 10.1016/S0140-6736(14)61909-7. PubMed DOI

Zeng J., Luo S., Huang Y., Lu Q. Critical role of environmental factors in the pathogenesis of psoriasis. J. Dermatol. 2017;34:863–872. doi: 10.1111/1346-8138.13806. PubMed DOI

Perez-Chada L.M., Merola J.F. Comorbidities associated with psoriatic arthritis: Review and update. Clin. Immunol. 2020;214:108397. doi: 10.1016/j.clim.2020.108397. PubMed DOI

Huang P. A comprehensive definition for metabolic syndrome. Dis. Model. Mech. 2009;2:231–237. doi: 10.1242/dmm.001180. PubMed DOI PMC

Samson S.L., Garber A.J. Metabolic Syndrome. Endocrinol. Metab. Clin. N. Am. 2014;43:1–23. doi: 10.1016/j.ecl.2013.09.009. PubMed DOI

Diane A., Pierce W.D., Kelly S.E., Sokolik S., Borthwick F., Jacome-Sosa M., Mangat R., Pradillo J.M., Allan S.M., Ruth M.R., et al. Mechanisms of Comorbidities Associated with the Metabolic Syndrome: Insights from the JCR:LA-cp Corpulent Rat Strain. Front. Nutr. 2016;3 doi: 10.3389/fnut.2016.00044. PubMed DOI PMC

De Felice C., Marulli G.C., Ardigò M., Berardesca E. Biological markers in the etiology of psoriasis: Targeted treatment options. Biol. Targets Ther. 2007;1:11–18. PubMed PMC

Coimbra S. Biomarkers of psoriasis severity and therapy monitoring. World J. Dermatol. 2014;3:15. doi: 10.5314/wjd.v3.i2.15. DOI

Qian M., Song N.-J. Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors. Eur. Rev. Med. Pharmacol. Sci. 2018;22:4299–4309. PubMed

Zlibut A., Agoston-Coldea L., Mocan T., Bocsan I.C., Mocan L. Biomarkers in Metabolic Syndrome. Ultimat. Guide Insulin. 2019 doi: 10.5772/intechopen.79427. DOI

Michel D., Chatelain G., North S., Brun G. Stress-induced transcription of the clusterin/apoJ gene. Biochem. J. 1997;328:45–50. doi: 10.1042/bj3280045. PubMed DOI PMC

Jin G., Howe P.H. Regulation of Clusterin Gene Expression by Transforming Growth Factor β. J. Biol. Chem. 1997;272:26620–26626. doi: 10.1074/jbc.272.42.26620. PubMed DOI

Trougakos I.P., Lourda M., Antonelou M.H., Kletsas D., Gorgoulis V.G., Papassideri I.S., Zou Y., Margaritis L.H., Boothman D.A., Gonos E.S. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin. Cancer Res. 2009;15:48–59. doi: 10.1158/1078-0432.CCR-08-1805. PubMed DOI PMC

Itakura E., Chiba M., Murata T., Matsuura A. Heparan sulfate is a clearance receptor for aberrant extracellular proteins. J. Cell Biol. 2020;219 doi: 10.1083/jcb.201911126. PubMed DOI PMC

Essabbani A., Margottin-Goguet F., Chiocchia G. Identification of Clusterin Domain Involved in NF-κB Pathway Regulation. J. Biol. Chem. 2009;285:4273–4277. doi: 10.1074/jbc.C109.057133. PubMed DOI PMC

Shim Y.-J., Kang B.-H., Choi B.-K., Park I.-S., Min B.-H. Clusterin induces the secretion of TNF-α and the chemotactic migration of macrophages. Biochem. Biophys. Res. Commun. 2012;422:200–205. doi: 10.1016/j.bbrc.2012.04.162. PubMed DOI

McDonald J.F., Nelsestuen G.L. Potent Inhibition of Terminal Complement Assembly by Clusterin: Characterization of Its Impact on C9 Polymerization†. Biochemistry. 1997;36:7464–7473. doi: 10.1021/bi962895r. PubMed DOI

Seo H.-Y., Kim M.K., Jung Y.-A., Jang B.K., Yoo E.K., Kim M.K., Lee I.K. Clusterin Decreases Hepatic SREBP-1c Expression and Lipid Accumulation. Endocrinology. 2013;154:1722–1730. doi: 10.1210/en.2012-2009. PubMed DOI

Won J.C., Park C.-Y., Oh S.W., Lee E.S., Youn B.S., Kim M.S. Plasma Clusterin (ApoJ) Levels Are Associated with Adiposity and Systemic Inflammation. PLoS ONE. 2014;9:e103351. doi: 10.1371/journal.pone.0103351. PubMed DOI PMC

Gil S.Y., Youn B.S., Byun K., Huang H., Namkoong C., Jang P.-G., Lee J.-Y., Jo Y.-H., Kang G.M., Kim H.-K., et al. Clusterin and LRP2 are critical components of the hypothalamic feeding regulatory pathway. Nat. Commun. 2013;4:1862. doi: 10.1038/ncomms2896. PubMed DOI

Williams S.E., Brown T.I., Roghanian A., Sallenave J.-M. SLPI and elafin: One glove, many fingers. Clin. Sci. 2005;110:21–35. doi: 10.1042/CS20050115. PubMed DOI

Guyot N., Zani M.-L., Berger P., Dallet-Choisy S., Moreau T. Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): Evidence for tryptase-mediated generation of elafin. Biol. Chem. 2005;386 doi: 10.1515/BC.2005.047. PubMed DOI

Elgharib I., Khashaba S.A., Elsaid H.H., Sharaf M.M. Serum elafin as a potential inflammatory marker in psoriasis. Int. J. Dermatol. 2018;58:205–209. doi: 10.1111/ijd.14217. PubMed DOI

Tanaka N., Fujioka A., Tajima S., Ishibashi A., Hirose S. Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: Interleukin-1β and tumour necrosis factor-α stimulate its secretion in vitro. Br. J. Dermatol. 2000;143:728–732. doi: 10.1046/j.1365-2133.2000.03766.x. PubMed DOI

Rabinovitch M. EVE and beyond, retro and prospective insights. Am. J. Physiol. Content. 1999;277:L5–L12. doi: 10.1152/ajplung.1999.277.1.L5. PubMed DOI

Guyot N., Butler M.W., McNally P., Weldon S., Greene C.M., Levine R.L., O’Neill S.J., Taggart C.C., McElvaney N.G. Elafin, an Elastase-specific Inhibitor, Is Cleaved by Its Cognate Enzyme Neutrophil Elastase in Sputum from Individuals with Cystic Fibrosis. J. Biol. Chem. 2008;283:32377–32385. doi: 10.1074/jbc.M803707200. PubMed DOI PMC

Simpson A.J., Maxwell A., Govan J., Haslett C., Sallenave J.-M. Elafin (elastase-specific inhibitor) has anti-microbial activity against Gram-positive and Gram-negative respiratory pathogens. FEBS Lett. 1999;452:309–313. doi: 10.1016/S0014-5793(99)00670-5. PubMed DOI

Bermúdez-Humarán L.G., Motta J.-P., Aubry C., Kharrat P., Martin L., Sallenave J.-M., Deraison C., Vergnolle N., Langella P. Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci. Microb. Cell Factories. 2015;14:26. doi: 10.1186/s12934-015-0198-4. PubMed DOI PMC

Salihbegovic E.M., Hadzigrahic N., Cickusic A.J. Psoriasis and Metabolic Syndrome. Med. Arch. 2015;69:85–87. doi: 10.5455/medarh.2015.69.85-87. PubMed DOI PMC

Borská L., Kremláček J., Andrys C., Krejsek J., Hamakova K., Borsky P., Palička V., Řeháček V., Málková A., Fiala Z. Systemic Inflammation, Oxidative Damage to Nucleic Acids, and Metabolic Syndrome in the Pathogenesis of Psoriasis. Int. J. Mol. Sci. 2017;18:2238. doi: 10.3390/ijms18112238. PubMed DOI PMC

Narendra G., Roshin N.A., Thimmappa V., Shivanna R. Metabolic syndrome in patients with psoriasis: A hospital-based case–control study. Clin. Dermatol. Rev. 2018;2:64–68. doi: 10.4103/CDR.CDR_41_17. DOI

Das S., Manna A., Ahmad N., Banerjee D., Mondal S., Tayal P. Psoriasis and metabolic syndrome: Co-incidence or correlation. Med. J. Dr. D.Y. Patil Univ. 2016;9:177. doi: 10.4103/0975-2870.167986. DOI

Al-Mutairi N., Al-Farag S., Al-Mutairi A., Al-Shiltawy M. Comorbidities associated with psoriasis: An experience from the Middle East. J. Dermatol. 2010;37:146–155. doi: 10.1111/j.1346-8138.2009.00777.x. PubMed DOI

Buquicchio R., Foti C., Loconsole F., Polimeno L., Ventura M.T. Clusterin serum level: How does it affect psoriatic patients? [(accessed on 1 May 2020)];J. Biol. Regul. Homeost. Agents. 2017 31:785–789. Available online: http://www.ncbi.nlm.nih.gov/pubmed/28958138. PubMed

Ataseven A., Kesli R., Kurtipek G.S., Ozturk P. Assessment of Lipocalin 2, Clusterin, Soluble Tumor Necrosis Factor Receptor-1, Interleukin-6, Homocysteine, and Uric Acid Levels in Patients with Psoriasis. Dis. Markers. 2014;2014:1–7. doi: 10.1155/2014/541709. PubMed DOI PMC

García-Rodríguez S., Arias-Santiago S., Perandrés-López R., Orgaz-Molina J., Castellote L., Buendía-Eisman A., Ruiz J., Naranjo R., Navarro P., Sancho J., et al. Decreased Plasma Levels of Clusterin in Patients With Psoriasis. Actas Dermo-Sifiliográficas (English Edition) 2013;104:497–503. doi: 10.1016/j.adengl.2012.11.018. PubMed DOI

Devauchelle V., Essabbani A., De Pinieux G., Germain S., Tourneur L., Mistou S., Margottin-Goguet F., Anract P., Migaud H., Le Nen D., et al. Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis. J. Immunol. 2006;177:6471–6479. doi: 10.4049/jimmunol.177.9.6471. PubMed DOI

Sol I.S., Kim Y.H., Lee K.E., Hong J.Y., Na Kim M., Kim Y.S., Oh M.S., Kim M.J., Yoon S.H., Park Y.A., et al. Serum clusterin level in children with atopic dermatitis. Allergy Asthma Proc. 2016;37:335–339. doi: 10.2500/aap.2016.37.3953. PubMed DOI

Vranová H.P., Hényková E., Mareš J., Kaiserová M., Menšíková K., Vaštík M., Hluštík P., Zapletalová J., Strnad M., Stejskal D., et al. Clusterin CSF levels in differential diagnosis of neurodegenerative disorders. J. Neurol. Sci. 2016;361:117–121. doi: 10.1016/j.jns.2015.12.023. PubMed DOI

Giang J., Seelen M.A.J., Van Doorn M.B.A., Rissmann R., Prens E.P., Damman J. Complement Activation in Inflammatory Skin Diseases. Front. Immunol. 2018;9 doi: 10.3389/fimmu.2018.00639. PubMed DOI PMC

Kim T.-G., Kim D.S., Kim H.-P., Lee M.-G. The pathophysiological role of dendritic cell subsets in psoriasis. BMB Rep. 2014;47:60–68. doi: 10.5483/BMBRep.2014.47.2.014. PubMed DOI PMC

Hong G.H., Kwon H.-S., Moon K.-A., Park S.Y., Park S., Lee K.Y., Ha E.H., Kim T., Moon H.-B., Lee H., et al. Clusterin Modulates Allergic Airway Inflammation by Attenuating CCL20-Mediated Dendritic Cell Recruitment. J. Immunol. 2016;196:2021–2030. doi: 10.4049/jimmunol.1500747. PubMed DOI

Savkovic V., Gantzer H., Reiser U., Selig L., Gaiser S., Sack U., Klöppel G., Mössner J., Keim V., Horn F., et al. Clusterin is protective in pancreatitis through anti-apoptotic and anti-inflammatory properties. Biochem. Biophys. Res. Commun. 2007;356:431–437. doi: 10.1016/j.bbrc.2007.02.148. PubMed DOI

Cunin P., Beauvillain C., Miot C., Augusto J.-F., Preisser L., Blanchard S., Pignon P., Scotet M., Garo E., Fremaux I., et al. Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses. Cell Death Dis. 2016;7:e2215. doi: 10.1038/cddis.2016.113. PubMed DOI PMC

Santarlasci V., Maggi L., Capone M., Frosali F., Querci V., De Palma R., Liotta F., Cosmi L., Maggi E., Romagnani S., et al. TGF-β indirectly favors the development of human Th17 cells by inhibiting Th1 cells. Eur. J. Immunol. 2009;39:207–215. doi: 10.1002/eji.200838748. PubMed DOI

Jenne D.E., Lowin B., Peitsch M.C., Bottcher A., Schmitz G., Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J. Biol. Chem. 1991;266:11030–11036. PubMed

Balantinou E., Trougakos I.P., Chondrogianni N., Margaritis L.H., Gonos E.S. Transcriptional and posttranslational regulation of clusterin by the two main cellular proteolytic pathways. Free. Radic. Biol. Med. 2009;46:1267–1274. doi: 10.1016/j.freeradbiomed.2009.01.025. PubMed DOI

Kratzer A., Giral H., Landmesser U. High-density lipoproteins as modulators of endothelial cell functions: Alterations in patients with coronary artery disease. Cardiovasc. Res. 2014;103:350–361. doi: 10.1093/cvr/cvu139. PubMed DOI

Nizard P., Tetley S., Le Dréan Y., Watrin T., Le Goff P., Wilson M., Michel D. Stress-Induced Retrotranslocation of Clusterin/ApoJ into the Cytosol. Traffic. 2007;8:554–565. doi: 10.1111/j.1600-0854.2007.00549.x. PubMed DOI

Fujita H., Yagishita N., Aratani S., Saito-Fujita T., Morota S., Yamano Y., Hansson M.J., Inazu M., Kokuba H., Sudo K., et al. The E3 ligase synoviolin controls body weight and mitochondrial biogenesis through negative regulation of PGC -1β. EMBO J. 2015;34:1042–1055. doi: 10.15252/embj.201489897. PubMed DOI PMC

Wei J., Yuan Y., Chen L., Xu Y., Zhang Y., Wang Y., Yang Y., Peek C.B., Diebold L., Yang Y., et al. ER-associated ubiquitin ligase HRD1 programs liver metabolism by targeting multiple metabolic enzymes. Nat. Commun. 2018;9:3659. doi: 10.1038/s41467-018-06091-7. PubMed DOI PMC

Li N., Zoubeidi A., Beraldi E., E Gleave M. GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer. Oncogene. 2012;32:1933–1942. doi: 10.1038/onc.2012.212. PubMed DOI

Li F., Gao B., Dong H., Shi J., Fang D. Icariin Induces Synoviolin Expression through NFE2L1 to Protect Neurons from ER Stress-Induced Apoptosis. PLoS ONE. 2015;10:e0119955. doi: 10.1371/journal.pone.0119955. PubMed DOI PMC

Widenmaier S., Snyder N.A., Nguyen T.B., Arduini A., Lee G.Y., Arruda A.P., Saksi J., Bartelt A., Hotamisligil G.S. NRF1 Is an ER Membrane Sensor that Is Central to Cholesterol Homeostasis. Cell. 2017;171:1094–1109.e15. doi: 10.1016/j.cell.2017.10.003. PubMed DOI

Shimoura N., Nagai H., Fujiwara S., Jimbo H., Nishigori C. Exacerbation and Prolongation of Psoriasiform Inflammation in Diabetic Obese Mice: A Synergistic Role of CXCL5 and Endoplasmic Reticulum Stress. J. Investig. Dermatol. 2018;138:854–863. doi: 10.1016/j.jid.2017.10.023. PubMed DOI

Sugiura K., Muro Y., Futamura K., Matsumoto K., Hashimoto N., Nishizawa Y., Nagasaka T., Saito H., Tomita Y., Usukura J. The Unfolded Protein Response Is Activated in Differentiating Epidermal Keratinocytes. J. Investig. Dermatol. 2009;129:2126–2135. doi: 10.1038/jid.2009.51. PubMed DOI

Arnold T., Brandlhofer S., Vrtikapa K., Stangl H., Hermann M., Zwiauer K., Mangge H., Karwautz A., Huemer J., Koller D., et al. Effect of Obesity on Plasma Clusterin: A Proposed Modulator of Leptin Action. Pediatr. Res. 2011;69:237–242. doi: 10.1203/PDR.0b013e31820930cb. PubMed DOI

Kloučková J., Lacinová Z., Kaválková P., Trachta P., Kasalický M., Haluzíková D., Mráz M., Haluzík M. Plasma Concentrations and Subcutaneous Adipose Tissue mRNA Expression of Clusterin in Obesity and Type 2 Diabetes Mellitus: The Effect of Short-Term Hyperinsulinemia, Very-Low-Calorie Diet and Bariatric Surgery. Physiol. Res. 2016:481–492. doi: 10.33549/physiolres.933121. PubMed DOI

Wang J., Ortiz C.W., Mukhopadhyay R., Fontenot L., Koon H.W. Mo2017 – Antimicrobial Peptide Elafin Reverses Obesity, Insulin Resistance, and Liver Steatosis Via Circulating Exosomal Mir181B-5P and Mir219-5P. Gastroenterology. 2019;156 doi: 10.1016/S0016-5085(19)39280-7. DOI

Korkmaz B., Horwitz M.S., Jenne D.E., Gauthier F. Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases. Pharmacol. Rev. 2010;62:726–759. doi: 10.1124/pr.110.002733. PubMed DOI PMC

Papayannopoulos V., Metzler K.D., Hakkim A., Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J. Cell Biol. 2010;191:677–691. doi: 10.1083/jcb.201006052. PubMed DOI PMC

Lingling S., Zhong L., Hoo R., Xu A. Pharmacological Inhibition of Neutrophil Elastase Attenuates Insulitis and Autoimmune Diabetes in Mice. Diabetes. 2018;67:1732. doi: 10.2337/db18-1732-P. DOI

Tsai Y.-S., Tseng Y.-T., Chen P.-S., Lin M.-C., Wu C.-C., Huang M.-S., Wang C.-C., Chen K.-S., Lin Y.-C., Wang T.-N. Protective effects of elafin against adult asthma. Allergy Asthma Proc. 2016;37:15–24. doi: 10.2500/aap.2016.37.3932. PubMed DOI

Henriksen P.A., Hitt M., Xing Z., Wang J., Haslett C., Riemersma R.A., Webb D.J., Kotelevtsev Y.V., Sallenave J.-M. Adenoviral Gene Delivery of Elafin and Secretory Leukocyte Protease Inhibitor Attenuates NF-κB-Dependent Inflammatory Responses of Human Endothelial Cells and Macrophages to Atherogenic Stimuli. J. Immunol. 2004;172:4535–4544. doi: 10.4049/jimmunol.172.7.4535. PubMed DOI

Butler M.W., Robertson I., Greene C.M., O’Neill S.J., Taggart C.C., McElvaney N.G. Elafin Prevents Lipopolysaccharide-induced AP-1 and NF-κB Activation via an Effect on the Ubiquitin-Proteasome Pathway. J. Biol. Chem. 2006;281:34730–34735. doi: 10.1074/jbc.M604844200. PubMed DOI

Motta J.-P., Magne L., Descamps D., Rolland C., Squarzoni–Dale C., Rousset P., Martin L., Cenac N., Balloy V., Huerre M., et al. Modifying the Protease, Antiprotease Pattern by Elafin Overexpression Protects Mice From Colitis. Gastroenterology. 2011;140:1272–1282. doi: 10.1053/j.gastro.2010.12.050. PubMed DOI

The Presence of Psoriasis, Metabolic Syndrome and Their Combination Increases the Serum Levels of CRP and CD5L but Not sCD200R1 and sTLR2 in Participants

Significantly Altered Serum Levels of NAD, AGE, RAGE, CRP, and Elastin as Potential Biomarkers of Psoriasis and Aging-A Case-Control Study

Aging in psoriasis vulgaris: female patients are epigenetically older than healthy controls